| Baseline | 3-months follow-up | 6-months follow-up | Change between Baseline and 3-months follow-up | Change between Baseline and 6-months follow-up | Change between 3-months and 6-months follow-up | Effect Size Baseline to 6-months follow-up |
---|---|---|---|---|---|---|---|
n; mean (sd), median | n; mean (sd), median | n; mean (sd), median | beta/ OR p value 95% CI | beta/ OR p value 95% CI | beta/ OR p value 95% CI | ||
n(%)a | n(%)a | n(%)a | Â | Â | Â | Â | |
 | Analyses on patient level |  |  |  |  | ||
 | n = 82 | n = 77 | n = 64 |  |  |  |  |
Pediatric rheumatologist | |||||||
 Physician’s global about JIA disease activity, VAS, 0–100 | 71; 34.0 (28.7); 30 | 64; 17.0 (22.6); 10 | 57; 13.4 (22.4); 5 | −17.7 < 0.001–23.29; −12.14 | −20.2 < 0.001–26.09; −14.41 | −2.5 0.401–8.46; 3.38 | 0.66 |
 Number of joints with active arthritis | 83; 0.6 (1.5); 0 | 77; 0.4 (1.5); 0 | 64; 0.9 (3.8); 0 | −0.1 0.636–0.77; 0.47 | 0.3 0.313–0.32; 1.00 | 0.5 0.152–0.18; 1.15 | 0.10 |
Patients reported outcomes | |||||||
 Overall well-being; VAS; 0–100 | 47; 34.1 (29.7); 26 | 43; 23.5 (20.3); 20 | 30; 23.2 (22.3); 12 | −10.5 0.003–17.48; −3.62 | −13.1 0.001–20.93; −5.27 | − 2.6 0.524–10.39; 5.29 | 0.41 |
 C-HAQ, 0–3 | 35; 0.81 (1.04); 0.5 | 27; 0.69 (0.88); 0.5 | 18; 0.52 (0.59); 0.44 | − 0.2 0.056–0.45; 0.01 | − 0.3 0.014–0.61; − 0.07 | −0.1 0.4–0.39; 0.16 | 0.13 |
 PedsQL, 0–100 | 52; 78.7 (21.5); 87.8 | 40; 81.7 (17.9); 86.9 | 26; 85.5 (13.5); 89.7 | 3.8 0.088–0.57; 8.21 | 7.2 0.006 2.08; 12.30 | 3.4 0.201–1.80; 8.54 | 0.15 |
 Number of days in hospital due to uveitis | 40; 1.9 (6.0); 0 | 32; 0.7 (2.7); 0 | 19; 1.1 (4.2); 0 | −1.2 0.274–3.33; 0.94 | −0.7 0.561–3.26; 1.77 | 0.4 0.736–2.16; 3.06 | 0.25 |
 Missed days in kindergarden/ school due to uveitis | 51; 4.8 (6.7); 1 | 47; 3.2 (9.2); 0 | 32; 0.5 (1.6); 0 | −1.7 0.211–4.30; 0.95 | −4.3 0.004–7.25; − 1.34 | −2.6 0.085–5.61; 0.37 | 0.20 |
 Number of days with restrictions in daily life due to uveitis | 39; 7.4 (16.9); 0 | 32; 1.7 (4.8); 0 | 19; 5.0 (10.6); 0 | −5.9 0.037–11.40; − 0.36 | −2.7 0.417–9.25; 3.83 | 3.2 0.355–3.55; 9.90 | 0.44 |
 | Analyses on eye level |  |  |  |  | ||
 | n = 147 | n = 132 | n = 103 |  |  |  |  |
Ophthalmologist | |||||||
 Physician’s global about disease activity in the eyes, VAS, 0–100 | 113; 45.2 (33.9); 50 | 111; 30.6 (33.5); 20 | 87; 25.2 (32.3); 14 | −15.0 < 0.001–19.13; − 10.83 | −20.0 < 0.001–24.57; − 15.44 | − 5.0 0.029–9.55; − 0.51 | 0.43 |
 Total number of AC cells | 46; 7.4 (6.4); 7.5 | 28; 1.4 (3.2); 0 | 33; 1.9 (4.8); 0 | −4.9 < 0.001–6.99; − 2.79 | − 5.0 < 0.001–7.03; − 2.91 | −0.1 0.942–2.29; 2.12 | 1.10 |
 Visual acuity, logMAR | 119; 0.48 (0.51); 0.3 | 101; 0.39 (0.50); 0.1 | 86; 0.42 (0.52); 0.11 | −0.1 0.015–0.11; − 0.01 | −0.1 0.062–0.10; 0.00 | 0.0 0.727–0.04; 0.06 | 0.18 |
 AC cell grade | 136; 2.81 (1.25); 3 | 116; 1.81 (1.20); 1 | 93; 1.39 (0.82); 1 | −1.0 < 0.001–1.26; − 0.80 | −1.5 < 0.001–1.72; − 1.22 | −0.4 0.001–0.69; − 0.19 | 0.81 |
 AC flare grade (no flare versus flare), SUN | 99 (70.2%) | 49 (38.6%) | 24 (25.3%) | 0.1 < 0.001 0.03; 0.21 | 0.0 < 0.001 0.01; 0.08 | 0.3 0.006 0.12; 0.71 | 0.67 |
 AC flare grade (no flare versus flare), MIWGUC | 53 (61.6%) | 31 (37.4%) | 17 (25.8%) | 0.1 < 0.001 0.03; 0.34 | 0.0 < 0.001 0.01; 0.14 | 0.3 0.032 0.09; 0.90 | 0.50 |
 Any structural complications | 81 (56.3%) | 73 (56.2%) | 64 (62.1%) | 0.9 0.867 0.27; 2.99 | 1.1 0.904 0.28; 4.28 | 1.2 0.79 0.30; 4.77 | 0.01 |
 Ocular hypotony | 3 (2.1%) | 3 (2.4%) | 0 (0.0%) | b | b | b | 0.02 |
 Ocular hypertension | 6 (4.3%) | 8 (6.5%) | 4 (4.1%) | 6.2 0.235 0.31; 124.32 | 0.2 0.321 0.01; 4.05 | 0.0 0.109 0.00; 2.06 | 0.09 |
 Posterior synechiae | 60 (43.2%) | 60 (46.2%) | 53 (52.0%) | 5.7 0.23 0.33; 96.67 | 4.7 0.324 0.21; 104.42 | 0.8 0.903 0.05; 15.33 | 0.06 |
 Glaucoma | 6 (4.4%) | 6 (5.1%) | 5 (5.4%) | b | b | b | 0.03 |
 Cataract | 28 (19.9%) | 23 (18.3%) | 24 (23.5%) | b | b | b | 0.04 |
 Band keratopathy | 31 (21.5%) | 31 (24.6%) | 27 (26.7%) | 25.6 0.067 0.80; 826.75 | 14.8 0.132 0.44; 493.90 | 0.6 0.716 0.03; 11.13 | 0.07 |
 Optic disc edema | 10 (10.9%) | 6 (7.0%) | 3 (4.8%) | b | b | b | 0.11 |
 Macular edema (Funduscopy) | 9 (7.0%) | 4 (5.0%) | 2 (2.9%) | 0.3 0.288 0.04; 2.68 | 0.2 0.195 0.02; 2.14 | 0.7 0.811 0.06; 9.42 | 0.07 |
 Macular edema (OCT) | 14 (21.5%) | 4 (12.5%) | 2 (6.1%) | b | b | b | 0.08 |
 Epiretinal membrane formation (Funduscopy) | 7 (5.5%) | 7 (8.5%) | 4 (5.9%) | b | b | b | 0.12 |
 Epiretinal membrane formation (OCT) | 7 (11.3%) | 7 (17.5%) | 5 (14.3%) | b | b | b | 0.11 |
 Vitreous haze (yes/no) | 15 (16.3%) | 15 (18.3%) | 13 (19.1%) | 1.6 0.518 0.38; 6.97 | 1.5 0.632 0.31; 6.75 | 0.9 0.89 0.20; 4.11 | 0.06 |
 Other complications | 12 (12.8%) | 2 (2.4%) | 0 (0.0%) | b | b | b | 0.10 |